ABSTRACT: Phosphocitrate inhibits cartilage degeneration, however, the prospect of phosphocitrate as an oral disease modifying drug might be limited. The purpose of this study was to investigate the biological effects and disease-modifying activity of a phosphocitrate "analog," CM-01 (Carolinas Molecule-01), and test the hypothesis that CM-01 is a disease modifying drug for osteoarthritis therapy. The effects of CM-01 on calcium crystal-induced expression of matrix metalloproteinase-1 and interleukin-1 beta, cell-mediated calcification and production of proteoglycan by chondrocytes were examined in cell cultures. Disease-modifying activity was examined using Hartley guinea pig model of posttraumatic osteoarthritis. Cartilage degeneration in untreated and CM-01 treated guinea pigs was examined with Indian ink and Safranin-O-fast green. Levels of matrix metalloproteinase-13, ADAM metallopeptidase with thrombospondin type 1 motif 5, chemokine (C-C motif) ligand 5, and cyclooxygenase 2 were examined with immunostaining. CM-01 inhibited crystal-induced expression of matrix metalloproteinase-1 and interleukin-1b, reduced cell-mediated calcification, and stimulated the production of proteoglycan by chondrocytes. In Hartley guinea pigs, CM-01 not only reduced damages in articular surface but also reduced resorption of calcified zone cartilage. The reduction in cartilage degeneration was accompanied by decreased levels of matrix metalloproteinase-13, ADAM metallopeptidase with thrombospondin type 1 motif 5, chemokine (C-C motif) ligand 5 and cyclooxygenase 2. These findings confirmed that CM-01 is a promising candidate to be tested as an oral drug for human OA therapy. CM-01 exerted its disease-modifying activity on osteoarthritis, in part, by inhibiting the production of matrix-degrading enzymes and a molecular program resembling the endochondral pathway of ossification. ß
Osteoarthritis (OA) is one of the most prevalent causes of disability in the aging population and has enormous economic and social consequences. However, existing non-surgical treatments only provide symptomatic relief and have no effects on the progression of cartilage degeneration. There is a pressing need for the development of structural disease-modifying drug that not only provides symptomatic relief, but also inhibits the progression of cartilage degeneration. The lack of progress in the development of structural OA disease-modifying drug is largely due to our limited understanding of the pathogenesis of OA and insufficient knowledge regarding the molecular targets for therapeutic intervention.
Pathogenesis of OA involves multiple etiologies, including mechanical, biochemical, and genetic factors that contribute to the imbalance in synthesis and destruction of articular cartilaginous matrices. It is believed that a complex network of biochemical factors, including matrix metalloproteinases (MMPs), ADAM metallopeptidase with thrombospondin type 1 motif 5 (Adamts5), and many inflammatory cytokines such as interlukin-1 beta (IL-1b) and cyclooxygenase-2 (Cox-2) are involved in the initiation or progression of OA. Pathological calcification is also a contributing factor. Basic calcium phosphate (BCP) and calcium pyrophosphate dihydrate (CPPD) crystals are present in the joint fluid, articular cartilage, and menisci of patients with end-stage of OA. [1] [2] [3] [4] These crystals stimulate cell mitogenesis, endocytotic activity, and the production of MMPs and inflammatory cytokines, and induce severe inflammatory response when injecting into the knee joints of animals. [5] [6] [7] [8] [9] Activation and abnormal phenotypic change of articular chondrocytes have been implicated in the formation of calcium crystal, chondrocyte apoptosis and cartilaginous matrix degradation. Chondrocytes in OA articular cartilage display an aberrant phenotype and actively produce MMP-13 and Adamts5. [10] [11] [12] OA-prone Hartley guinea pigs develop OA spontaneously and exhibit progressive degenerative changes in articular cartilage that closely resemble the degenerative changes in human OA. [13] [14] [15] [16] Hartley guinea pigs have been widely used to study the pathogenesis of OA and test potential OA disease-modifying drugs. Phosphocitrate (PC) is a powerful calcification inhibitor, which prevents soft tissue calcification, and displays no toxic side effect in rats in doses up to 150 mmol/kg/day. 17, 18 PC also inhibits crystal-induced cell membrane damages, mitogenesis, expression of extracellular matrix-degrading enzymes, and crystalinduced cell death. [19] [20] [21] [22] These findings provided support for the hypothesis that PC is a potentially disease-modifying drug for calcification-induced or crystal-associated OA therapy. 23 A subsequent study demonstrated that PC inhibited meniscal calcification in Hartley guinea pigs, and that the reduction in meniscal calcification was accompanied with decreased cartilage degeneration. 24 It was believed that PC exerted its OA disease modifying activity by inhibiting the formation of articular crystals and the detrimental interaction between these crystals and joint cells. 23, 24 We recently demonstrated that PC inhibited the expression of numerous genes implicated in OA in the absence of calcium crystals in cell cultures and that PC inhibited cartilage degeneration in a Hartley guinea pig model of posttraumatic OA. [25] [26] [27] [28] These findings indicate that PC is not only a disease modifying drug for crystal-associated primary OA therapy, but also a disease modifying drug for injury-induced secondary posttraumatic OA therapy. However, the prospect of PC as an oral disease modifying drug might be limited. The P-O-C bond within PC is vulnerable to degradation in vivo by alkaline phosphatases and the five negative charges possessed by PC may make PC less permeable to intestine membrane. 29 In this study, we sought to examine the biological effects and OA disease modifying activity of a PC "analog," CM-01 (Coralinas Molecule-01), and test the hypothesis that CM-01 is potentially OA disease modifying drug for both injury-induced secondary posttraumatic OA and crystal-associated primary OA. CM-01 is a small molecule that has structural similarities to PC, yet is resistant to alkaline phosphatases and has fewer negative charges. If CM-01 displays a strong OA disease-modifying activity in our animal study, CM-01 will be a promising small molecule candidate to be tested as an oral disease modifying drug for human OA therapy.
MATERIALS AND METHODS
Dulbecco's modified eagle medium (DMEM), STEMPro chondrogenesis medium, fetal bovine serum (FBS), antibiotic and antimycotic solution, and Hank's balanced salt solution were products of Invitrogen (Carlsbad, CA).
45
Calcium was obtained from Perkin-Elmer (Boston, MA). Safranin-O and fast green were obtained from Polysciences (Warrington, PA). Antibodies specific to Adamts5 and Cox-2 were obtained from Santa Cruz Biotechnology (Dallas, TX). Antibodies specific to MMP-13 and chemokine (C-C motif) ligand 5 (CCL-5) were obtained from Lifespan Biosciences (Seattle, WA) and Bioss (Woburn, MA), respectively. CM-01 was obtained from a commercial source, and formulated in our laboratory.
Cells
Primary OA fibroblast-like synoviocytes (FLSs) and OA chondrocytes were prepared from synovial and cartilage specimens collected from end-stage OA patients undergoing joint replacement surgery at Carolinas Medical Center with the approval of Institutional Review Board. The need for informed consent was waived because those specimens were surgical waste, and no private patient information was collected. Briefly, synovial tissues or articular cartilage specimens were minced into small pieces with a surgical blade, and cultured in 100 mm plates at 37˚C in medium containing 10% serum. Culture medium was changed every 3 days. After cells reached 70% confluence, they were passaged. OA FLSs and chondrocytes with 2-3 passages were used in our experiments. Human foreskin fibroblasts were obtained from American Type Culture Collection (CRL-2429, Manassas, VA).
Inhibition of Crystal-Induced Expressions of MMP-1 and IL-b
Human foreskin fibroblasts are used extensively to evaluate the effect of calcium crystals and the effects of PC on the expression of MMPs and cytokines. 9, 21, 22, [30] [31] [32] It is proposed that PC binds to the surface of crystals and block the interaction between crystals and cells, and in so doing, inhibits crystal-induced expression of MMPs. 23 To evaluate the potential of CM-01 as a disease-modifying drug for crystal-associated OA therapy, we examined the effect of CM-01 on BCP crystals-induced expression of MMP-1 and interlukin-1b (IL-1b) following the procedure previously described. 21, 22 Briefly, human foreskin fibroblasts were plated in six 60 mm plates at 95% confluence. The cells were rendered quiescent by incubation in DMEM containing 0.5% FBS for 24 h. On the next day, the six plates were divided into three groups. The first group (two plates) was cultured in DMEM containing 0.5% FBS without BCP crystals and CM-01. The second group (two plates) was cultured in DMEM containing 0.5% FBS and BCP crystals (50 mg/ml). The last group (two plates) was cultured in DMEM containing 0.5% FBS and BCP crystals (50 mg/ml) with added CM-01 (1 mM). Twenty-four hours later, total RNA was extracted from these cells using Trizol Reagent (Invitrogen, Carlsbad, CA). Semi-quantitative RT-PCR was performed (ThermoScript RT-PCR System, Invitrogen) with specific primers of MMP-1 and IL-1b 33 to determine the messenger RNA levels of MMP-1 and IL-1b. This experiment was repeated two times.
Inhibition of OA Cell-Mediated Calcification
OA FLSs play a role in pathological calcification. [34] [35] [36] To examine the effect of CM-01 on calcification, we examined the effect of CM-01 on OA FLSs-mediated calcification as described. 36 Briefly, OA FLSs were plated in a 24-wells cluster plate at 95% confluence. The cells were rendered quiescent by incubation in DMEM containing 0.5% FBS for 24 h. On the next day, DMEM containing 1 mM ATP and trace-labeled with 1 mCi/ml 45 calcium was added, followed immediately by increasing amounts of CM-01 (triplicates). Forty-eight hours later, these cells were washed with cold Hank's balanced salt solution five times and lysed with 0.1 N NaOH. Radioactivity of the lysate, count per minute (CPM), in each well was quantified using liquid scintigraphy. This experiment was repeated three times. Results were presented as normalized calcifications, which were calculated by diving the CMP obtained from OA FLSs treated with CM-01 (0.0, 0.1, 0.25, and 0.5 mM, respectively) by the CMP obtained from OA FLSs without CM-01 treatment.
Effect of CM-01 on cell-mediated calcification was also examined with OA chondrocytes using the 45 calcium deposition assay as described. In addition, it was examined with OA chondrocytes cultured in STEMPro chondrogenesis medium. Briefly, OA chondrocytes were plated in 24-wells plates at 85-90% confluence. On the next day, these wells were divided into three groups. The first group cells (three wells) was cultured in STEMPro chondrogenesis differentiation medium without ATP and CM-01. The second group cells (three wells) was cultured in STEMPro chondrogenesis differentiation medium containing ATP (1 mM). The last group cells (three wells) was cultured in STEMPro chondrogenesis differentiation medium containing ATP (1 mM) and CM-01 (0.5 mM). These chondrocytes were cultured for 9 days and fed with fresh STEMPro chondrogenesis differentiation medium at the conditions indicated every 3 days. At
the end of experiment period, media were removed from all wells and chondrocytes in each well were stained with alizarin red. Alizarin red stains were extracted from each well with 200 ml acidic water (0.1 mM hydrogen chloride) and quantified by reading at 405 nm using a microplate reader. This experiment was repeated three times. Results were presented as normalized calcifications, which were calculated by diving the reading at 405 nm obtained from chondrocytes treated with ATP and CM-01 by the CMP obtained from chondrocytes without APT and CM-01 treatment.
Effect of CM-01 on the Production of Proteoglycan by OA Chondrocytes OA chondrocytes were harvested from 100 mm plates and suspended in DMEM. For preparing a micromass, a droplet of the chondrocyte suspension containing 2 Â 10 5 cells was placed in a well in a 24-wells plate. After placing eight droplets, the plate was incubated for 5 h in a 37˚C culture incubator to form micromass. These micromasses were fed with STEMPro chondrogenesis differentiation medium and divided into two groups. The first group (three micromasses) was fed with STEMPro chondrogenesis differentiation medium in the absence of CM-01 and the second group (three micromasses) was fed with STEMPro chondrogenesis differentiation medium containing 0.5 mM CM-01. These micromasses were cultured for 14 days and fed with fresh STEMPro chondrogenesis differentiation medium at the conditions indicated every 3 days. At the end of experiment, each well was rinsed twice with 500 ml of Hank's balanced salt solution. Two drops of eosin were added to each well. Five minutes later, eosin was aspirated off and the micromasses were transferred individually to a strip of filter paper which sat on the top of an ethanol-soaked sponge within a plastic cassette. The cassettes sat in a 10% formalin solution for 1 h. These micromasses then underwent routine paraffin embedding. Sections were cut at 5 mm, and stained with alcian blue or alizarin red. This experiment was repeated two times.
Experimental Animals
Animal study was performed following the guidelines set forth by the Institutional Animal Care & Use Committee of Carolinas Medical Center, which approved the animal protocol. One-month old male Hartley guinea pigs (345 AE 40 g) were obtained from Charles River Laboratories (Wilmington, MA) and individually housed in 29 Â 21 Â 10-inchs solid bottom cages. Guinea Pig Chow (No. 5025; Ralston Purina, Richmond, IN) and water were available ad libitum. When reaching 2-month old, these guinea pigs were randomly divided into two groups. The first group (n ¼ 5) received intraperitoneal injection of CM-01 (40 mg/kg) twice per week and the second group (n ¼ 5) received physiological saline. Two months later, partial medial meniscectomy was performed on the right knee of all guinea pigs. A week after the surgery, injection of CM-01 or saline was resumed. Five months later, these guinea pigs were euthanized by the administration of Euthasol (Virbac Animal Health, Ft. Worth, TX). Hind limbs were collected, fixed in 10% formalin, and transferred to 70% ethanol until use. Previous studies have shown that five guinea pigs in the control and experimental group were sufficient to assess OA disease modifying activity of small molecule drugs. 24, 28 Radiographic, Microscopic, and Histological Examinations Radiographs of knee joints were obtained with a digital radiography system (piXaray 100, Bioptics Inc., Tucson, AZ). After radiographic examinations, the knee joints were dissected and menisci were removed. The medial menisci from the left knee of all guinea pigs were examined radiographically. The area of calcified anterior horn was measured using the measuring tool in Adobe acrobat software (San Jose, CA). Briefly, radiographic imaging files of the medial meniscus of the left knee were opened with Adobe acrobat software (professional version) and the calcified anterior horn was traced with the "pen" in the measuring tool. When tracing was finished, the area of calcified horn was automatically calculated by the software.
The tibial plateaus of the right knee were first examined with Indian ink staining. After Indian ink examination, these tibial plateaus were decalcified in a formic acid/sodium citrate solution (Fisher Scientific, Fairlawn, NJ) and cut coronally in the center to produce two equal portions. The posterior portion was embedded in paraffin and sectioned (4 mm) with a Leica RM2025 microtome (Nussloch, Germany). Three non-consecutive sets of sections (three consecutive sections in each set) obtained at 400 mm intervals were stained with Safranin-O-fast green. These sections (total nine sections per tibial plateau) were graded blindly by YS and AR independently following the standard Mankin criteria with minor modifications. 15 The scores were presented as the mean AE standard deviation (SD).
Thickness of Articular Cartilage and Cartilage Bars or Islands
Thickness of articular cartilage and the volume of cartilage bars within subchondral bone were determined by using NIH ImageJ photo analysis software (version 1.8.0_45). Briefly, the central areas of three safranin-O-fast green stained sections from each tibial plateau were captured with a digital camera (Sony DXC-S500) equipped with a microscope (Nikon Optiphot-2). The cartilage and cartilage bars (red color) were selected using following Image thresholding and LAB color space parameters (L: 0/255, A: 145/255, B: 0/255). After selection, the area of articular cartilage (particle size setting: 0.1 to infinity) and the total area of cartilage bars (particle size setting: 0.0001-0.1) were measured. Thickness of articular cartilage was obtained by dividing the area of cartilage with the length of the cartilage measured. "Thickness" of the cartilage bars was obtained by dividing the total area of cartilage bars with the length of the cartilage measured. Normalized cartilage thicknesses were used in all analyses.
Immunostaining
Two sections from each tibial plateau were deparaffinized with xylene and rehydrated with graded ethanol. Endogenous peroxidase was blocked by incubation with deionized water containing 3% H 2 O 2 . Non-specific binding was blocked by incubation with 100 ml of 10% normal horse serum diluted in a base solution (4% BSA and 5% non-fat dry milk in PBS) for 20 min. These sections were incubated with primary antibodies (1:100 dilution) for 1 h, followed with a secondary reagent for 30 min (Immpress reagent kit, Vector, Inc., Burlingame, CA). Negative control was performed using mouse IgG. Slides were rinsed in phosphate buffered saline three times and visualized with 3, 3 0 -diaminobenzidine. These slides were graded on a scale of 0-4 as previously described. 28, 37 Total 10 sections from each group were examined and graded. The scores were presented as the mean AE standard SD.
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Statistical Analyses
Results were presented as mean AE SD. After performing normality and equal variance tests (passed), the differences in calcification between different CM-01 concentration points were analyzed with one-way ANOVA and Student's t-test. The difference in meniscal calcification and cartilage thickness between untreated and CM-01 treated guinea pig groups was analyzed with Student's t-test. Histologic and immunostaining scores (variables presented as ordinal data) were also presented as the mean AE SD. The differences in the scores between CM-01 treated and untreated guinea pig group was evaluated using the Wilcoxon rank sum test. These data passed normality and equal variance tests, therefore, the difference between control and CM-01 treated group was analyzed using Student's t-test. It was considered significant when p-value was less than 0.05. Statistical analysis was performed using statistical analysis tool in Sigma Plot software, version 12 (Systat Software, Inc., San Jose, CA).
RESULTS
CM-01 Inhibited BCP Crystal-Induced Expression of MMP-1 and IL-1b
The hypothesis that PC is a potentially diseasemodifying drug for crystal-associated primary OA therapy was proposed in part based on the findings that PC inhibited calcium crystal-induced expression of MMP-1 and IL-1b in human foreskin fibroblast culture, 9, 21, 23 To test the potential of CM-01 as a disease modifying drug for crystal-associated primary OA therapy, we examined the effect of CM-01 on BCP crystal-induced expression of MMP-1 and IL-1b in human foreskin fibroblast culture. As shown in Figure 1 , BCP crystals induced the expression of MMP-1 and IL-1b in the human foreskin fibroblast culture and that CM-01 inhibited the BCP crystalsinduced increase of messenger RNA levels of MMP-1 and IL-1b almost completely, suggesting that CM-01 is potentially a disease modifying drug for crystal-associated primary OA therapy.
CM-01 Inhibited Cell-Mediated Calcification
Next, we examined the effect of CM-01 on OA cellmediated calcification. As shown in Figure 2A , CM-01 inhibited OA FLSs-mediated calcification in a dosedependent manner. The calcification inhibitory activity of CM-01 was about 8% to 19% less powerful than PC, depending on its concentration (0.25 or 0.5 mM). We also examined the effect of CM-01 on OA chondrocytemediated calcification using the same 45 calcium deposition assay and a different calcification assay using chondrocytes cultured in STEMPro chondrogenesis differentiation medium. 36 Similarly, CM-01 strongly inhibited OA chondrocyte-mediated calcium deposition in both assays (Fig. 2B and C) , confirming that CM-01 was a powerful calcification inhibitor. In addition, we examined the effect of CM-01 on proteoglycan production by OA chondrocytes in the absence of calcium crystals. As shown in Figure 2D , CM-01 stimulated proteoglycan production by OA chondrocytes in the absence of calcium crystals, indicating that CM-01 has a crystal-independent biological activity that is potentially chondroprotective. These results together indicate that CM-01 is not only potentially a disease modifying drug for crystal-associated primary OA but also for non-crystal-induced OA such as injury-induced secondary posttraumatic OA therapy.
CM-01 Reduced Meniscal Calcification in Hartley Guinea Pigs
Cell culture studies indicate that CM-01 is potentially a disease modifying drug for OA therapy, therefore, we procced with animal study. Representative radiographs of the knee joints and the medial meniscus dissected from the left knee of the guinea pigs were provided in Figure 3 . As expected, calcified medial meniscus was observed in non-operated left knee, but not in the meniscectomied right knee (Fig. 3A) . The anterior horn appeared less calcified in the left knee of guinea pigs treated with CM-01 than in the left knee of untreated control guinea pigs (Fig. 3A and B) , indicating by the smaller size of the calcified anterior horn in the guinea pigs treated with CM-01. We dissected the knee joints, removed the medial meniscus from the left knees and examined them radiographically. As shown in Figure 3C , severe calcification occurred only in the anterior horn (solid arrow), but not in the posterior horn (line arrow). We measured the area of the calcified anterior horn from all guinea pigs and found that CM-01 treatment resulted in 9.2% reduction in the size of the calcified anterior horn (p ¼ 0.046).
CM-01 Inhibited Cartilage Degeneration
As shown in Figure 4A , cartilage damages, visualized with Indian ink staining, spanned a larger area of the medial tibial plateaus in the untreated guinea pigs than in the CM-01 treated guinea pigs. Cartilage damages occurred not only in the central area (green arrow) but also in the peripheral area originally covered with medial meniscus (red arrow). Cartilage damages were much less severe, especially in the peripheral area (red arrow), in the CM-01 treated guinea pigs compared to the untreated guinea pigs. Consistent with Indian ink staining, safranin-O-fast green staining revealed that cartilage degeneration was more severe in the untreated guinea pigs (Fig. 4B) . Cartilage damages and proteoglycan loss extended into the deep zone, and in some cases, into the calcified zone. In contrast, only mild to moderate cartilage damages were noted in the CM-01 treated guinea pigs and proteoglycan loss was confined within the superficial and middle zones. Structural damages and proteoglycan loss were rarely seen in the peripheral area in the CM-01 treated guinea pigs (red arrows). These safranin-O-fast green stained sections INHIBITION OF OA by CM-01 were graded as described. As shown in Figure 4C , CM-01 treatment significantly reduced the histologic score (white bars), resulting in a 35% reduction in the histological scores in the right knee (p ¼ 0.002). Sections in the non-operated left knee were also graded (gray bars). CM-01 treatment resulted in a 39% reduction in the histological scores in the non-operated left knee (p ¼ 0.001).
There were some other differences between these sections. The first difference was that tidemark was more visible and closer to articular surface in untreated guinea pigs than in the CM-01 treated guinea pigs (solid black arrows). The second difference was that cartilage was thinner in untreated guinea pigs and the third difference was that there were fewer cartilage bars or islands within the subchondral bone in the untreated guinea pigs compared to the CM-01 treated guinea pigs (open black arrows). These differences indicate more severe advance of the calcification front toward noncalcified cartilage and more active replacement of the calcified cartilage by subchondral bone in the untreated guinea pigs compared to the CM-01 treated guinea pigs. In other word, subchondral bone advance toward articular surface may play a role in articular cartilage thinning in the untreated guinea pigs. CM-01 exerted its disease modifying activity, in part, by inhibiting the subchondral bone advance. As shown in Figure 4D , the articular cartilage in the central area of medial tibial plateau was 26% thinner in the untreated guinea pigs than in the CM-01 treated guinea pigs. When including the cartilage bars into the calculation, the articular cartilage in the central area of medial tibial plateau was 34% thinner in the untreated guinea pigs than in the CM-01 treated guinea pigs.
CM-01 Treatment
Reduced the levels of Adamts5, MMP-13, CCL-5, and Cox-2 As shown in Figure 5A high levels of Adamts5 were detected in the superficial and middle zones (solid black arrow), whereas high levels of MMP-13 were mainly detected in the middle and deep zones (open black arrow) in the untreated guinea pigs. Consistent with its inhibitory activity on cartilage degeneration, CM-01 treatment reduced the levels of Adamts5, and MMP-13, resulting in 26% and 38% reductions in the immunostaining scores of Adamts5 (p ¼ 0.047) and MMP-13 (p ¼ 0.031), respectively (Fig. 5B) . High levels of CCL-5 were detected in the superficial and middle zones in the central area of the medial tibial plateau (solid black arrow), whereas high levels of Cox-2 were mainly detected in peripheral area (open black arrow), but not in the central area (solid black arrow), in the untreated guinea pigs (Fig. 5C ). CM-01 treatment reduced the levels of both CCL-5 and Cox-2, resulting in 46% (p ¼ 0.021), and 31% (p ¼ 0.046) reductions in the immunostaining score of CCL-5 and Cox-2, respectively (Fig. 5D) . 
DISCUSSION
We demonstrated in this study that CM-01, a small molecule "analog" of PC, inhibited BCP crystal-induced expressions of MMP-1 and IL-1b, and reduced OA cell-mediated calcium deposition, while stimulated proteoglycan production by OA chondrocytes in the absence of calcium crystals. These findings indicate that CM-01 is a strong calcification inhibitor and potentially a disease-modifying drug for both crystalassociated primary OA and non-crystals-induced OA such as injury-induced secondary posttraumatic OA therapy. Indeed, CM-01 treatment in the Hartley guinea pigs reduced meniscal calcification, and inhibited cartilage degeneration in both the partial meniscectomied right knees and the non-operated left knees. The reduction in articular cartilage degeneration in CM-01 treated guinea pigs was accompanied with decreased expressions of Adamts5 and MMP-13. In addition, CM-01 treatment reduced the levels of inflammatory proteins CCL-5 and Cox-2, indicating that CM-01 is also an anti-inflammation agent, consistent with our previous findings. 25, 26 It appeared that CM-01 was slightly less powerful than PC in the inhibition of cartilage degeneration. CM-01 treatment resulted in a 35% reduction in the histological score and 26% increase in cartilage thickness whereas as PC treatment resulted in a 46% reduction in the histological score and 31% increase in cartilage thickness in the same guinea pig model of posttraumatic OA. 28 Nevertheless, the findings demonstrated in this study confirmed that CM-01 is structural OA disease-modifying small molecule.
The main function of calcified zone is to fasten the articular cartilage to subchondral bone. In this study, we found that the tidemark was more visible and closer to articular surface and there were fewer articular cartilage bars within the subchondral bone in the untreated guinea pigs compared to the CM-01 treated guinea pigs. These findings suggest that cartilage degeneration might progress from both the articular surface and calcified zone toward the inner zones. Degenerative insults to articular cartilage came from both the articular side and the epiphyseal side. The degenerative insults from the epiphyseal side may not only result in articular cartilage thinning but may also weaken the connection between the calcified zone cartilage and the underlying subchondral bone. Calcified zone articular chondrocytes might recapitulate a developmental molecular program resembling the endochondral pathway of ossification. These articular chondrocytes might obtain properties resembling terminal differentiating chondrocytes. These differentiating articular chondrocytes stimulate calcification, apoptosis and neovascularization, 11, 12, [38] [39] [40] and may participate in cartilage degeneration by secreting large amounts of MMPs. 41, 42 This re-activated molecular program might play a role in the advance of calcification front and resorption of the calcified zone cartilage by the subchondral bone during OA progression. CM-01 exerts its disease modifying activity on OA, likely in part, by inhibiting this re-activated molecular program.
In summary, CM-01 is a powerful calcification inhibitor and proteoglycan production-stimulator. CM-01 exerts its disease modifying activity on OA, at least in part, by inhibiting a molecular program resembling endochondral pathway of ossification and reducing the production of matrix degrading enzymes and inflammatory cytokine by OA chondrocytes. CM-01 is likely a more promising small molecule candidate than PC to be tested as an oral disease modifying drug for human OA therapy because CM-01 is an "analog" that is resistance to alkaline phosphatases and contains fewer negative charges than the molecule PC.
Our study has limitations. Because CM-01 was administered through injection before partial menis- cectomy surgery, our study only proved that CM-01 administered through injection could prevent cartilage degeneration, but provided no information about its potential or effectiveness as a therapeutic disease modifying drug to treat established intermediate OA or advanced OA. Additional studies, which are planning in our laboratory, are needed to evaluate the therapeutic disease modifying effect of CM-01 administered through injection or orally on established intermediate OA or advanced OA in the Hartley guinea pigs before investing its potential as a disease modifying drug for human OA therapy. 
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